 |
[Alpha Biz=(Chicago) Reporter Paul Lee] Celltrion Pharmaceutical's operating profit in the third quarter of this year was cut by half due to a drop in drug prices following the generic reassessment.
According to Celltrion Pharmaceutical's announcement on the 14th, operating profit in the third quarter of this year was 6.55191 billion won, down 51% from 13.46447 billion won in the third quarter of last year.
Sales in the third quarter were 93.38468 billion won, down 10% from the same period last year.
On a cumulative basis in the third quarter, it recorded sales of 2,936 billion won and operating profit of 30.88 billion won, respectively.
During the same period, autoimmune disease drugs and breast and gastric cancer drugs maintained a domestic market share of more than 30%, and grew 9.2% and 1.5%, respectively, compared to the same period last year.
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
